Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273621 | 0.86 | CHUK (0.54) | MAPTCHEK1PARP1AURKACCNB2 | |
| SCHEMBL16011911 | 0.86 | CHUK (0.54) | MAPTCHEK1PARP1AURKACCNB2 | |
| SCHEMBL2628369 | 0.79 | KIF11 (0.58) | MAPTCHEK1PARP1AURKAGABRP | |
| SCHEMBL21070513 | 0.79 | MAPT (0.49) | MAPTCHEK1PARP1AURKACCNB2 | |
| SCHEMBL1586081 | 0.79 | MAPT (0.49) | MAPTCHEK1PARP1AURKACDK5 | |
| SCHEMBL1181804 | 0.79 | MAPT (0.49) | MAPTCHEK1PARP1AURKAALDH1A1 | |
| SCHEMBL3454039 | 0.79 | PARP1 (0.68) | MAPTPARP1AURKACCNB2CDK1 | |
| SCHEMBL3453963 | 0.79 | AURKA (0.68) | MAPTPARP1AURKACCNB2CDK1 | |
| SCHEMBL17967686 | 0.78 | MAPT (0.55) | MAPTCHEK1PARP1AURKACDK5 | |
| SCHEMBL406033 | 0.78 | PARP1 (0.67) | CHEK1PARP1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3817748-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | CRBN, CRKL, CUL4A | MAPT 1069/4885CHEK1 272/4885PARP1 2805/4885 |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | CRBN, CRKL, CUL4A | MAPT 1069/4885CHEK1 272/4885PARP1 2805/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | MAPT 1069/4885CHEK1 272/4885PARP1 2805/4885 |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | MAPT 1069/4885CHEK1 272/4885PARP1 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.